{
    "documentMetadata": {
        "title": "Cellulitis, Erysipelas_ Diabetes mellitus",
        "sourceFile": "Cellulitis, Erysipelas_ Diabetes mellitus.pdf",
        "lastUpdated": "2022-04-07"
    },
    "content": [
        {
            "type": "header",
            "level": 1,
            "text": "Clinical Setting"
        },
        {
            "type": "list",
            "items": [
                "Patient with diabetes mellitus peripheral neuropathy, suffers inflammation of the skin and subcutaneous tissue.",
                "May have contiguous skin ulceration and/or atherosclerotic peripheral vascular disease."
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Etiologies"
        },
        {
            "type": "list",
            "items": [
                "Streptococcus sp. (Group A, B, C, G)",
                "Staph. aureus",
                "Enterobacterales",
                "Anaerobes (bad prognosis if present)"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Primary Regimens"
        },
        {
            "type": "list",
            "items": [
                "Assess adequacy of arterial blood supply.",
                "May need surgical debridement for cultures to determine or assess for contiguous osteomyelitis and for presence of necrotizing fasciitis.",
                "Early or mild infection:",
                "TMP-SMX double strength 1-2 tabs po bid + (Penicillin VK 500 mg po qid or Cephalexin 500 mg po qid)"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Alternative Regimens"
        },
        {
            "type": "list",
            "items": [
                "Early or mild infection:",
                "Omadacycline",
                "200 mg IV (over 60 min) loading dose and then 100 mg (over 30 min) q24 h OR",
                "100 mg IV over 30 min BID on day one and then 100 mg iv over 30 min q24h OR",
                "450 mg PO q24h on days 1 and 2 and then 300 mg PO q24h",
                "Do not use an older tetracycline for reason of resistance and/or clinical failures.",
                "For hospitalized patient with severe disease, forced to use broad spectrum therapy that targets both Staph. aureus and Enterobacterales:",
                "(Imipenem 0.5 gm IV q6h) PLUS either",
                "Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 \u00b5g/mL x hr (see vancomycin AUC dosing calculator); alternative target is trough of 15-20 \u00b5g/mL",
                "Daptomycin 4 mg/kg IV q24h",
                "Linezolid 600 mg IV/po bid",
                "Can substitute another Carbapenem for Imipenem: Ertapenem 1 gm IV q24h or Doripenem 500 mg IV q8h or Meropenem 1 gm IV q8h"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Comments"
        },
        {
            "type": "list",
            "items": [
                "Other alternatives to the Carbapenem: Levofloxacin, Piperacillin-tazobactam",
                "Caution re hyperkalemia with TMP-SMX in those with reduced renal function or concomitant drugs causing hyperkalemia",
                "Likelihood of Contiguous Osteomyelitis is increased if you can probe to the bone. Low likelihood of contiguous osteomyelitis if probe is negative. Clin Infect Dis 47:510, 2008.",
                "Pai MP, et al. J Antimicrob Chemother. 2021;76:1315-1322.",
                "Duane TM, et al. Surgical Infection Society 2020 Updated Guidelines; Surg Infect 2021; May 22(4):383-399."
            ]
        }
    ]
}